
Very proud and fortunate to be mentored by Dr. Neugut, who won the @columbiacancer Mentor of the Year Award
✓Passion for cancer research and clinical oncology. Radiation Oncology at MSKCC. #CancerOutcomes #NeuroOnc #CancerMetabolism

Very proud and fortunate to be mentored by Dr. Neugut, who won the @columbiacancer Mentor of the Year Award

As treatment options continue to evolve, keeping prognostic tools up to date is essential for guiding treatment for patients with brain metastases. Grateful to be part of this incredible team! #BrainMetastases #Radonc #GPA #prognosis @OhioStateRadOnc sciencedirect.com/science/ar…


7/n Age >40 is a surrogate for IDH in g 2-3 glioma, but is not prognostic in IDH-mut glioma or predictive of benefit from CRT. Age >40 in isolation should not be an indication for adjuvant therapy. Guidelines should be updated to reflect contemporary prognostic factors.

6/n Pooling RCTs of CRT vs RT for grade 2-3 IDH-mutant glioma, age >40 was not predictive of benefit from CRT over RT alone.

5/n Features of "molecular GBM" were more common in IDH-wt tumors in patients >40 YO, in-part explaining the prognostic significance in this subgroup.


3/n Age >40 was not prognostic in IDH-mutant glioma, but was prognostic in IDH-mutant lower grade glioma (interaction <.001).

2/n We determined if age is prognostic/predictive in grade 2-3 gliomas or merely a surrogate for IDH status. We evaluated almost 3,000 patients, many from major cooperative group trials. Age predicted IDH status (95% vs. 62% IDH-mutant over/under 40 YO).

1/n Virtually every RCT of CRT for LGG used age ≥40 yrs as inclusion. Every major guidelines still cites age as a high-risk factor for LGG


Pleasure to have a colleague notify me today that our article is in print in the @JCO_ASCO "Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas" ascopubs.org/doi/full/10.120…

1/6: I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO! doi.org/10.1200/JCO-25-02730 There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer. We asked: 1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR? 2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification? 🧵👇

Fantastic work led by @dtbergman analyzing 3,893 patients treated with Linac SRS for brain mets. OS plateaus from 5-20 lesions & salvage WBRT is rare. Data support an SRS-first strategy over fixed lesion limits! doi.org/10.1093/noajnl/vdag2… @MSKCancerCenter @MSK_RadOnc

Excited to share our new paper out today in @NatureMetabolism! "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" *We bridged spatial metabolomics (MALDI-MSI glycomics + lipidomics + isotopic pulse-chase tracing) directly to experimental biochemistry (genetic knockdown of glycan enzymes + glucosamine supplementation in AD models) and real-world public health data (EHR analysis showing glucosamine use linked to faster MCI-to-AD progression and worse survival). **Key takeaway: The AD brain shows conserved hyperglycosylation driven by ramped-up glycan biosynthesis — not just a byproduct, but a causal driver. Reducing it helps cognition; boosting it (e.g., via glucosamine) worsens outcomes. ***We applied cutting-edge spatial tech to functional validation and clinical translation. Full open-access paper: nature.com/articles/s42255-0… Huge thanks to the incredible team, collaborators (incl. Matt Gentry, Stefan Prokop, @ji0ngbi0n , Yi Guo, @lichenbiostat, Ralph Deberardinis & others), and the patients/families who make this work possible.
